Literature DB >> 28682728

Improved Quality of Life After Transtibial Amputation in Patients With Diabetes-Related Foot Complications.

Dane K Wukich1, Junho Ahn1, Katherine M Raspovic2, Javier La Fontaine1, Larry A Lavery1.   

Abstract

The purpose of this study was to evaluate health-related quality of life after major lower-extremity amputation in a cohort of patients with diabetes mellitus. We evaluated 81 patients with diabetes and transtibial amputation (TTA) who had a minimum of 1 year of follow-up. Of these 81 patients, 50.6% completed the Short Form Survey (SF-36) and the Foot and Ankle Ability Measure (FAAM) preoperatively and postoperatively. Outcome measures before and after TTA were compared using Welch's ANOVA for continuous variables and Fisher's exact test for categorical variables. There was significant improvement in all 8 subscales of the SF-36, physical component summary (PCS) score, mental component summary (MCS) score, and the FAAM. The median SF-36 PCS score improved from 26.2 to 36.6 preoperatively versus postoperatively ( P < .0005). The postoperative PCS score improved in 75.6% of patients and worsened in 24.4%. The median SF-36 MCS score improved from 43.7 to 56.1 preoperatively versus postoperatively ( P < .0005). Both the FAAM activities of daily living (ADL; P < .005) and FAAM sports scores ( P < .05) improved significantly. The postoperative FAAM general/ADL score improved in 75.6% of patients and worsened in 24.4%. Patients who were nonambulatory postoperatively had significantly lower SF-36 general health subscale scores and lower FAAM scores than patients who were ambulatory postoperatively. In select patients with nonfunctional lower extremities resulting from instability and/or chronic infection, TTA can result in significant improvement in quality of life and lower-extremity function. We acknowledge that 25% of patients had a reduction in self-reported quality of life; however, 75% of patients improved their quality of life.

Entities:  

Keywords:  amputation; diabetes; lower extremity; outcomes; quality of life

Mesh:

Year:  2017        PMID: 28682728     DOI: 10.1177/1534734617704083

Source DB:  PubMed          Journal:  Int J Low Extrem Wounds        ISSN: 1534-7346            Impact factor:   2.057


  6 in total

1.  Investigating and Comparing the Effect of Teach-Back and Multimedia Teaching Methods on Self-Care in Patients With Diabetic Foot Ulcers.

Authors:  Somayyeh Babamir Satehi; Mitra Zandi; Homayoon Bana Derakhshan; Maliheh Nasiri; Tahmineh Tahmasbi
Journal:  Clin Diabetes       Date:  2021-04

Review 2.  Therapeutic Alternatives in Diabetic Foot Patients without an Option for Revascularization: A Narrative Review.

Authors:  Gerhard Ruemenapf; Stephan Morbach; Martin Sigl
Journal:  J Clin Med       Date:  2022-04-12       Impact factor: 4.964

3.  Sarcopenia increases the risk for mortality in patients who undergo amputation for diabetic foot.

Authors:  You Keun Kim; Ho Seong Lee; Jae Jung Ryu; Hye In Lee; Sang Gyo Seo
Journal:  J Foot Ankle Res       Date:  2018-06-19       Impact factor: 2.303

4.  [Diabetic foot syndrome-Part 2 : Revascularization, treatment alternatives, care structures, recurrency prophylaxis].

Authors:  G Rümenapf; S Morbach; U Rother; C Uhl; H Görtz; D Böckler; C A Behrendt; D Hochlenert; G Engels; A Hohneck; M Sigl
Journal:  Chirurg       Date:  2021-02       Impact factor: 0.955

5.  The PERCEIVE quantitative study: PrEdiction of Risk and Communication of outcome following major lower-limb amputation: protocol for a collaboratiVE study.

Authors:  Brenig L Gwilym; Cherry-Ann Waldron; Emma Thomas-Jones; Ryan Preece; Sarah Milosevic; Lucy Brookes-Howell; Philip Pallmann; Debbie Harris; Ian Massey; Jo Burton; Philippa Stewart; Katie Samuel; Sian Jones; David Cox; Adrian Edwards; Chris Twine; David C Bosanquet
Journal:  BJS Open       Date:  2021-11-09

6.  Deferring Amputation in Diabetic Foot Osteomyelitis: Doing More Harm Than Good?

Authors:  Shiwei Zhou; Brian M Schmidt; Oryan Henig; Keith S Kaye
Journal:  Open Forum Infect Dis       Date:  2021-04-14       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.